Press release
Entero's Grid AI Announces Major U.S. Expansion and Incoming Leadership to Accelerate AI Infrastructure Strategy
Entero Therapeutics, Inc. ("Entero") today announced that its wholly owned subsidiary, Grid AI, is finalizing the formation of a U.S.-based executive leadership team as the company accelerates its expansion into the rapidly scaling domestic market for AI-ready digital infrastructure and orchestration technologies.Image: https://www.globalnewslines.com/uploads/2025/11/239fa4cafd7b5877510f583eb5a810bb.jpg
Grid AI expects to announce the appointment of a U.S.-based Chief Executive Officer and Executive Chairman in the near term. The incoming leaders are seasoned public-market operators with extensive experience building and scaling global companies in the demand-response, energy-flexibility, and digital-infrastructure sectors. Their backgrounds align directly with Grid AI's mission to deliver integrated AI orchestration, energy-optimization, and intelligent infrastructure-control solutions for hyperscale and enterprise AI deployments.
The leadership expansion comes at a critical moment for the global compute and data-center ecosystem. This week, AMD CEO Dr. Lisa Su forecast that the global data-center market could reach $1 trillion by 2030, driven by unprecedented AI-compute demand. Supporting that growth could require more than 2,000 new data centers worldwide, each needing advanced AI-driven control systems, power orchestration, and real-time energy market optimization-the core capabilities of the Grid AI platform.
"With more than $50 million invested since 2019 to develop, test, and commercialize this autonomous platform, Grid AI is entering a new phase," said Jason Sawyer, CEO of Entero. "Building a dedicated U.S. leadership team enhances our execution capabilities and strengthens our ability to support large-scale AI-driven SaaS deployments across the domestic digital-infrastructure landscape."
Grid AI plans to provide further updates on leadership appointments, commercial initiatives, and its broader U.S. expansion strategy in the coming weeks.
The company's U.S. buildout supports Entero's long-term objective to capture value at the intersection of artificial intelligence, energy systems, and next-generation digital infrastructure.
About Entero Therapeutics, Inc.
Entero Therapeutics, Inc. is a technology company focused on solutions at the intersection of artificial intelligence, energy systems, and digital infrastructure. The company was founded in 2019 and operates through its wholly owned subsidiary, Grid AI. Entero is headquartered in the United States
Media Contact
Company Name: Entero Investor Relations
Contact Person: Jason Sawyer
Email: Send Email [http://www.universalpressrelease.com/?pr=enteros-grid-ai-announces-major-us-expansion-and-incoming-leadership-to-accelerate-ai-infrastructure-strategy]
City: Boca Raton
State: FL
Country: United States
Website: https://enterothera.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Entero's Grid AI Announces Major U.S. Expansion and Incoming Leadership to Accelerate AI Infrastructure Strategy here
News-ID: 4281178 • Views: …
More Releases from Getnews
A Long-Awaited Leadership Blueprint Arrives: The Undying Business Redefines What …
Image: https://www.globalnewslines.com/uploads/2026/01/a2b602bf3c5419a55c6cfb007174e051.jpg
In an era saturated with fleeting business trends, recycled motivational slogans, and surface-level leadership advice, a rare and substantive work has finally arrived.
The Undying Business: Lead Boldly, Build Intelligently, Endure Strategically by Mark Chiaravalloti is not another startup fantasy or mindset manifesto. It is a disciplined, battle-tested blueprint for leaders who are serious about building organizations that endure pressure, volatility, and time.
Written after nearly three decades of hands-on leadership,…
flynas Launches New Abha Operations Base in Cooperation with the Cluster2 Compan …
- flynas will connect Abha with 11 international and domestic destinations in the first phase.
- The leading LCC is to be the first Saudi airline to operate from five hubs in the Kingdom.
flynas, the leading low-cost airline in the world and the best LCC in the Middle East, announced the establishment of a new operations base at Abha International Airport in cooperation with the leading airports operator, Cluster2 company, and…
Milestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatm …
Image: https://www.globalnewslines.com/uploads/2026/01/1768400192.jpg
$NRXP has Entered into a Joint Offering with neurocare Group for Neuroplastic Therapy Targeting Depression, PTSD and Other Mental Health Afflictions
* Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
* Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
* D. Boral Analyst Report on NRXP $34 Price Target.
* 70,000 Patient Data on Real World…
Akram Alhamidi Releases Free 15-Minute Daily Clarity Checklist
Akram Alhamidi of Petal, Mississippi shares a simple, practical tool shaped by real-world business experience.
PETAL, MS - Akram Alhamidi, founder of a gas station, has released a free resource designed to help everyday individuals bring structure and clarity to their day. The new Daily Clarity Checklist is a short, practical self-audit that can be completed in 15 minutes and used immediately.
The checklist reflects Alhamidi's hands-on approach to leadership and decision-making.…
More Releases for Entero
Celiac Disease Treatment Market Set for Robust Growth Through 2034, Driven by Re …
The celiac disease treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Entero Therapeutics, Amgen/Provention Bio, Takeda, and Sanofi, among others.
DelveInsight's "Celiac Disease Market Insight, Epidemiology And Market Forecast - 2034" report delivers an in-depth understanding of the celiac disease treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France,…
Celiac Disease Pipeline 2025: Groundbreaking Clinical Advancements by 80+ Global …
DelveInsight's Celiac Disease Pipeline Insight, 2025 report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Celiac Disease pipeline landscape. It covers the Celiac Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Celiac Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Celiac Disease Pipeline products in this space.
DelveInsight's "Celiac Disease…
Gastroparesis Pipeline Drugs 2025 Report by DelveInsight: Strategic Intelligence …
DelveInsight's, "Gastroparesis Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Gastroparesis pipeline landscape. It covers the Gastroparesis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastroparesis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Gastroparesis…
Celiac Disease Pipeline 2025: Groundbreaking Clinical Advancements by 80+ Global …
With Celiac Disease reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Celiac Disease pipeline comprises 25+ pharmaceutical and biotech companies actively developing 30+ therapeutic candidates targeting Celiac Disease. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to…
Gastroparesis Pipeline Appears Robust With 8+ Key Pharma Companies Actively Work …
DelveInsight's, "Gastroparesis Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Gastroparesis pipeline landscape. It covers the Gastroparesis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastroparesis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Gastroparesis…
Celiac Disease Pipeline: Pioneering Progress with 25+ Leading Companies Developi …
The Celiac Disease market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Sanofi, Entero Therapeutics, Takeda, Pfizer, Topas Therapeutics, Anokion SA, Protagonist Therapeutics, and Equillium. These industry pioneers are transforming treatment strategies and redefining the future of Celiac Disease, bringing new hope to patients worldwide.
DelveInsight's "Celiac Disease Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Celiac…
